Tempest Therapeutics (TPST) Price & Analysis

Compare

1,251 Followers

TPST Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.35 - $20.67

Previous CloseN/A

Volume2.28M

Average Volume (3M)61.90K

Market Cap

$41.65M

Enterprise Value$20.24M

Total Cash (Recent Filing)$14.28M

Total Debt (Recent Filing)$8.66M

Price to Earnings (P/E)―

Beta1.55

Next Earnings

Nov 05, 2025

EPS Estimate

-3.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.07

Shares Outstanding4,440,161

10 Day Avg. Volume43,623

30 Day Avg. Volume61,899

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.49

Enterprise Value/Revenue41.65

Enterprise Value/Gross Profit2.02K

Enterprise Value/Ebitda-0.48

Forecast

1Y Price Target

$9.00

Price Target Upside-4.05% Downside

Rating ConsensusHold

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentTempest recently held a successful EOP2 meeting with the FDA, reaching a broad agreement on the Phase 3 study plan, including dose schedule and primary endpoint.

EarningsTempest posted EPS of ($3.16), which was better than both the analyst's estimate and the consensus estimate.

PartnershipsContinued support from Roche is seen as further validation of amezalpat's potential in changing the 1L HCC treatment landscape.

Bears Say

Funding NeedsTempest will still require a sizable cash infusion to fully support Phase 3 development, with management indicating it would cost approximately $100 million.

Market ConditionsThere is very deep frustration with Tempest's position due to the timing of data from Roche's MORPHEUS-Liver study and unprecedented conditions of the financial markets for healthcare funding.

Tempest Therapeutics News

Tempest Therapeutics Reports Q2 2025 Financial Results

Tempest Therapeutics, Inc. ( ($TPST) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

TPST

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

“We are pleased to see the continued progress of our clinical oncology portfolio, including the recent clearance in...

2M ago

TPST

Tempest Therapeutics, Inc. (TPST) Q2 Earnings Cheat Sheet

Tempest Therapeutics, Inc. (TPST) is scheduled to report 2nd quarter earnings on 08/07/2025. Regarding Q2 estimates, Wall Street...

2M ago

TPST

Morpheus-Liver Study: A New Horizon in Advanced Liver Cancer Treatment

Tempest Therapeutics, Inc. (($TPST)) announced an update on their ongoing clinical study. The Morpheus-Liver study, officially titled A...

2M ago

TPST

Tempest Therapeutics’ Promising Advances in Liver Cancer Treatment

Tempest Therapeutics, Inc. (($TPST)) announced an update on their ongoing clinical study. The clinical study titled A Study...

3M ago

TPST

Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial

Tempest Therapeutics (TPST) announced that the company received approval from the National Medical Products Administration in China to...

3M ago

TPST

Tempest Therapeutics Secures $4.1M in Direct Offering

The latest update is out from Tempest Therapeutics ( ($TPST) ). On June 11, 2025, Tempest Therapeutics entered...

4M ago

TPST

Tempest prices 739,000 shares at $6.25 in registered direct offering

Tempest Therapeutics (TPST) has entered into a definitive agreement with a single institutional investor for the purchase and...

4M ago

TPST

Tempest Therapeutics Shifts Executives to Consulting Roles

Tempest Therapeutics ( ($TPST) ) has issued an announcement. Tempest Therapeutics announced a strategic shift on June 5,...

4M ago

TPST

Tempest Therapeutics receives ODD from EMA for amezalpat

Tempest Therapeutics (TPST) announced that the European Medicines Agency, EMA, has granted Orphan Drug Designation, ODD, to amezalpat,...

4M ago

TPST

Tempest Therapeutics Reports Q1 2025 Financial Results

Tempest Therapeutics, Inc. ( ($TPST) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

TPST

Tempest Therapeutics: Navigating Financial Challenges with Promising Clinical Data and Strategic Partnerships

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on TPST stock, giving a Hold rating yesterday....

5M ago

TPST

Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)

“The amezalpat program continues to produce data that reinforce its potential as a cancer therapy, most recently in...

5M ago

TPST

Cautious Optimism for Tempest Therapeutics Amid Strategic Reorganization and Promising Amezalpat Data

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on TPST stock, giving a Hold rating on...

5M ago

TPST

TPST FAQ

What was Tempest Therapeutics’s price range in the past 12 months?

Tempest Therapeutics lowest stock price was $5.35 and its highest was $20.67 in the past 12 months.

What is Tempest Therapeutics’s market cap?

Tempest Therapeutics’s market cap is $41.65M.

When is Tempest Therapeutics’s upcoming earnings report date?

Tempest Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 37 days.

How were Tempest Therapeutics’s earnings last quarter?

Tempest Therapeutics released its earnings results on Aug 11, 2025. The company reported -$2.07 earnings per share for the quarter, beating the consensus estimate of -$3.23 by $1.16.

Is Tempest Therapeutics overvalued?

According to Wall Street analysts Tempest Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tempest Therapeutics pay dividends?

Tempest Therapeutics does not currently pay dividends.

What is Tempest Therapeutics’s EPS estimate?

Tempest Therapeutics’s EPS estimate is -3.27.

How many shares outstanding does Tempest Therapeutics have?

Tempest Therapeutics has 4,440,161 shares outstanding.

What happened to Tempest Therapeutics’s price movement after its last earnings report?

Tempest Therapeutics reported an EPS of -$2.07 in its last earnings report, beating expectations of -$3.23. Following the earnings report the stock price went up 9.988%.

Which hedge fund is a major shareholder of Tempest Therapeutics?

Currently, no hedge funds are holding shares in TPST

Tempest Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-322.57%

Trailing 12-Months

Asset Growth

-41.94%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tempest Therapeutics

Tempest Therapeutics (TPST) is a clinical-stage biotechnology company focused on developing small molecule therapeutics for the treatment of cancer. The company is engaged in the research and development of novel therapies that harness the body's immune system to combat tumors. Tempest Therapeutics operates within the biotechnology sector, with its core products centered around advancing its pipeline of targeted oncology treatments.